Associations - ER Y537S

ER Y537S	HER2 Negative Breast Cancer	ER Y537S	HER2 Negative Breast Cancer	H3B-6545 Sensitive: C2 – Inclusion Criteria H3B-6545 Sensitive : C2	H3B-6545 Sensitive: C2 – Inclusion Criteria H3B-6545 Sensitive : C2
ER Y537S	HER2 Negative Breast Cancer	ER Y537S	HER2 Negative Breast Cancer	SAR439859 Sensitive: C3 – Early Trials SAR439859 Sensitive : C3	SAR439859 Sensitive: C3 – Early Trials SAR439859 Sensitive : C3
ER Y537S	Estrogen Receptor Positive Breast Cancer	ER Y537S	Estrogen Receptor Positive Breast Cancer	fulvestrant Sensitive: C3 – Early Trials fulvestrant Sensitive : C3	fulvestrant Sensitive: C3 – Early Trials fulvestrant Sensitive : C3
ER Y537S	HER2 Negative Breast Cancer	ER Y537S	HER2 Negative Breast Cancer	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3
ER Y537S	Breast Cancer	ER Y537S	Breast Cancer	tamoxifen Sensitive: C4 – Case Studies tamoxifen Sensitive : C4	tamoxifen Sensitive: C4 – Case Studies tamoxifen Sensitive : C4
ER Y537S	Estrogen Receptor Positive Breast Cancer	ER Y537S	Estrogen Receptor Positive Breast Cancer	SAR439859 Sensitive: D – Preclinical SAR439859 Sensitive : D	SAR439859 Sensitive: D – Preclinical SAR439859 Sensitive : D
ER Y537S	Estrogen Receptor Positive Breast Cancer	ER Y537S	Estrogen Receptor Positive Breast Cancer	OP-1250 Sensitive: D – Preclinical OP-1250 Sensitive : D	OP-1250 Sensitive: D – Preclinical OP-1250 Sensitive : D
ER Y537S	Breast Cancer	ER Y537S	Breast Cancer	OP-1250 Sensitive: D – Preclinical OP-1250 Sensitive : D	OP-1250 Sensitive: D – Preclinical OP-1250 Sensitive : D
ER Y537S	Breast Cancer	ER Y537S	Breast Cancer	ZN-c5 Sensitive: D – Preclinical ZN-c5 Sensitive : D	ZN-c5 Sensitive: D – Preclinical ZN-c5 Sensitive : D
ER Y537S	Estrogen Receptor Positive Breast Cancer	ER Y537S	Estrogen Receptor Positive Breast Cancer	lasofoxifene Sensitive: D – Preclinical lasofoxifene Sensitive : D	lasofoxifene Sensitive: D – Preclinical lasofoxifene Sensitive : D
ER Y537S	Breast Cancer	ER Y537S	Breast Cancer	LY3484356 Sensitive: D – Preclinical LY3484356 Sensitive : D	LY3484356 Sensitive: D – Preclinical LY3484356 Sensitive : D
ER Y537S	Estrogen Receptor Positive Breast Cancer	ER Y537S	Estrogen Receptor Positive Breast Cancer	GDC-9545 Sensitive: D – Preclinical GDC-9545 Sensitive : D	GDC-9545 Sensitive: D – Preclinical GDC-9545 Sensitive : D
ER Y537S	Estrogen Receptor Positive Breast Cancer	ER Y537S	Estrogen Receptor Positive Breast Cancer	palbociclib + OP-1250 Sensitive: D – Preclinical palbociclib + OP-1250 Sensitive : D	palbociclib + OP-1250 Sensitive: D – Preclinical palbociclib + OP-1250 Sensitive : D
ER Y537S	Estrogen Receptor Positive Breast Cancer	ER Y537S	Estrogen Receptor Positive Breast Cancer	palbociclib Sensitive: D – Preclinical palbociclib Sensitive : D	palbociclib Sensitive: D – Preclinical palbociclib Sensitive : D
ER Y537S	Breast Cancer	ER Y537S	Breast Cancer	CB-103 Sensitive: D – Preclinical CB-103 Sensitive : D	CB-103 Sensitive: D – Preclinical CB-103 Sensitive : D
ER Y537S	Estrogen Receptor Positive Breast Cancer	ER Y537S	Estrogen Receptor Positive Breast Cancer	SCR-6852 Sensitive: D – Preclinical SCR-6852 Sensitive : D	SCR-6852 Sensitive: D – Preclinical SCR-6852 Sensitive : D
ER Y537S	Estrogen Receptor Positive Breast Cancer	ER Y537S	Estrogen Receptor Positive Breast Cancer	KPT-8602 Sensitive: D – Preclinical KPT-8602 Sensitive : D	KPT-8602 Sensitive: D – Preclinical KPT-8602 Sensitive : D

Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.